Case Study: The Patient Journey

In this case study module, program director Stephen Harrison describes the NASH patient journey, with reference to the disease course and management of a 65-year old NASH patient, including initial risk factors, diagnosis, management recommendations and emerging therapies in the field.

When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.

In support of improving patient care, this activity is accredited by North American Center for Continuing Medical Education (NACCME) for 0.25 AMA PRA Category 1 Credit(s)™. Should you wish to claim credits for this activity, please select “yes” in the question below and download your certificate. Should you simply wish to provide us with valuable feedback, please select “no” in the question below and submit your feedback.

Show more

Login or create a free account to get started



Learning objectives

Following completion of this activity, you will be able to:


Program Director

Stephen Harrison

Visiting Professor of Hepatology Radcliffe Department of Medicine, University of Oxford, UK
Medical Director, Pinnacle Clinical Research, Texas, USA
President, Summit Clinical Research, Texas, USA

Dr Harrison earned his medical degree from the University of Mississippi School of Medicine.  He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University.  He is board certified in both Internal Medicine and Gastroenterology.

Dr Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.  He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, Texas.


Grants – Akero, Axcella, Cirius, CiVi, Cymabay, Enyo, Galectin, Galmed Research & Dev., Genfit, Gilead Sciences, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM, Northsea, Novartis, Novo Nordisk, Poxel Sagimet, Viking

Consulting – AgomAB, Akero, Alentis, Alimentiv, Altimmune, Axcella, Boston Pharma, B Riley, BVF Partners, Canfite, CiVi, Corcept, Cymabay, Echosens, Enyo, Fibronostics, Foresite, Fortress, Galectin, Genfit, Gilead, GNS, Hepion, Hightide, HistoIndex, Inipharm, Intercept, Ionis, Kowa, Madrigal, Metacrine, Microba, NGM, NorthSea, Novartis, Novo Nordisk, Nutrasource, Piper Sandler, Poxel, Prometic Pharma, Ridgeline, Sagimet, Sonic Incytes, Terns, Vikings


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NACCME designates AMA PRA Category 1 Credit™ for the following activities:

  • Completion of 15-minute patient case study: 0.25 AMA PRA Category 1 Credit™
  • Completion of 15-minute eLearning module: 0.25 AMA PRA Category 1 Credit™
  • Completion of 20-minute video module: 0.25 AMA PRA Category 1 Credit™
  • Completion of all components listed above and the opening/closing videos: 1.0 AMA PRA Category 1 Credit™

How to claim your credits

To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.

Planning Committee

In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Kristin Kolack, Rachel Goddard, James Hutton, and Alba Ruzafa. The Planning Committee have no financial relationships to disclose.


This activity is supported by an educational grant from NOVO NORDISK A/S.